Approval

Approval  ·  Weekly Digest - 25 October to 31 October 2025
Enhertu approved in Canada as the first and only HER2-directed therapy for patients with HR-positive HER2-low or HER2-ultralow metastatic breast cancer, following disease progression after one or more endocrine therapies

Weekly Digest – October 2025 Weekly Digest – October 2025 29 October 2025: Enhertu approved in Canada as the first and only HER2-directed therapy for patients with HR-positive HER2-low or HER2-ultralow metastatic breast cancer, following disease progression after one or […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 25 October to 31 October 2025
Marketing approval obtained in China for Meiyouheng (Becotatug Vedotin injection)

Weekly Digest – October 2025 Weekly Digest – October 2025 30 October 2025: Marketing approval obtained in China for Meiyouheng (Becotatug Vedotin injection) The NMPA has granted marketing approval in China for Becotatug Vedotin injection, an innovative EGFR-targeted ADC developed […]

by Sandhya Ramalingam

Continue Reading